Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benjamin Lebecque

Showing results (11-20 of 22) with videos related to

Pageof 3
Sort By:
BMC Cancer|July 5, 2024
Correction: Value of combining biological age with assessment of individual frailty to optimize management of cancer treated with targeted therapies: model of chronic myeloid leukemia treated with tyrosine kinase inhibitors (BIO-TIMER trial)Mélanie Casile, Gilles Albrand, Clément Lahaye, et al.
BMC Cancer|May 30, 2024
Value of combining biological age with assessment of individual frailty to optimize management of cancer treated with targeted therapies: model of chronic myeloid leukemia treated with tyrosine kinase inhibitors (BIO-TIMER trial)Mélanie Casile, Gilles Albrand, Clément Lahaye, et al.
Pediatric Blood & Cancer|December 14, 2020
Double L611S/V617F JAK2 mutation in a child with erythrocytosisBenjamin Lebecque, Victoria Grèze, Thomas Tassin, et al.
Cancer|October 26, 2025
Optimizing Wilms tumor 1 thresholds for measurable residual disease monitoring in acute myeloid leukemia: Improved sensitivity and concordance with nucleophosmin 1 in a single-center validation studySabrina Barriere, Céline Bourgne, Thomas Tassin, et al.
Cancers|April 23, 2022
Deciphering Genetic Alterations of Hairy Cell Leukemia and Hairy Cell Leukemia-like Disorders in 98 PatientsElsa Maitre, Cécile Tomowiak, Benjamin Lebecque, et al.
British Journal of Haematology|March 3, 2024
Faster clinical decisions in B-cell acute lymphoblastic leukaemia: A single flow cytometric 12-colour tube improves diagnosis and minimal residual disease follow-upBenjamin Lebecque, Joevin Besombes, Louis-Thomas Dannus, et al.
Cancers|October 14, 2022
The Spliceosome: A New Therapeutic Target in Chronic Myeloid LeukaemiaBenjamin Lebecque, Celine Bourgne, Chinmay Munje, et al.
Scientific Reports|March 18, 2021
Efficiency of nilotinib to target chronic phase-chronic myeloid leukaemia primary mature CD34<sup>-</sup> and immature CD34<sup>+</sup> cellsMarc G Berger, Benjamin Lebecque, Thomas Tassin, et al.
Annals of Hematology|April 1, 2025
Contribution of molecular characterization to the diagnosis of MPN in patients with low JAK2<sup>V617F</sup> variant allelic fraction in a real-world cohortBenjamin Lebecque, Carolyne Croizier, Thomas Tassin, et al.
Ejhaem|July 18, 2022
Mast cell density and its clinical relevance in Waldenström's macroglobulinemiaRichard Lemal, Stéphanie Poulain, Albane Ledoux-Pilon, et al.
Pageof 3

Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
BMC Cancer|July 5, 2024
Correction: Value of combining biological age with assessment of individual frailty to optimize management of cancer treated with targeted therapies: model of chronic myeloid leukemia treated with tyrosine kinase inhibitors (BIO-TIMER trial)Mélanie Casile, Gilles Albrand, Clément Lahaye, et al.
BMC Cancer|May 30, 2024
Value of combining biological age with assessment of individual frailty to optimize management of cancer treated with targeted therapies: model of chronic myeloid leukemia treated with tyrosine kinase inhibitors (BIO-TIMER trial)Mélanie Casile, Gilles Albrand, Clément Lahaye, et al.
Pediatric Blood & Cancer|December 14, 2020
Double L611S/V617F JAK2 mutation in a child with erythrocytosisBenjamin Lebecque, Victoria Grèze, Thomas Tassin, et al.
Cancer|October 26, 2025
Optimizing Wilms tumor 1 thresholds for measurable residual disease monitoring in acute myeloid leukemia: Improved sensitivity and concordance with nucleophosmin 1 in a single-center validation studySabrina Barriere, Céline Bourgne, Thomas Tassin, et al.
Cancers|April 23, 2022
Deciphering Genetic Alterations of Hairy Cell Leukemia and Hairy Cell Leukemia-like Disorders in 98 PatientsElsa Maitre, Cécile Tomowiak, Benjamin Lebecque, et al.
British Journal of Haematology|March 3, 2024
Faster clinical decisions in B-cell acute lymphoblastic leukaemia: A single flow cytometric 12-colour tube improves diagnosis and minimal residual disease follow-upBenjamin Lebecque, Joevin Besombes, Louis-Thomas Dannus, et al.
Cancers|October 14, 2022
The Spliceosome: A New Therapeutic Target in Chronic Myeloid LeukaemiaBenjamin Lebecque, Celine Bourgne, Chinmay Munje, et al.
Scientific Reports|March 18, 2021
Efficiency of nilotinib to target chronic phase-chronic myeloid leukaemia primary mature CD34<sup>-</sup> and immature CD34<sup>+</sup> cellsMarc G Berger, Benjamin Lebecque, Thomas Tassin, et al.
Annals of Hematology|April 1, 2025
Contribution of molecular characterization to the diagnosis of MPN in patients with low JAK2<sup>V617F</sup> variant allelic fraction in a real-world cohortBenjamin Lebecque, Carolyne Croizier, Thomas Tassin, et al.
Ejhaem|July 18, 2022
Mast cell density and its clinical relevance in Waldenström's macroglobulinemiaRichard Lemal, Stéphanie Poulain, Albane Ledoux-Pilon, et al.
Pageof 3